Latest News

The company, which is quickly emerging as one of the leading biosimilar companies, is backing the European naming system over the American unique identifier.

A temporary new minister for the industry and innovation portfolio after Senator Arthur Sinodinos was granted extended leave for a medical issue.

MTPConnect and Life Sciences Queensland have signed a memorandum of understanding reinforcing their relationship and commitment to boost the Queensland and broader Australian life sciences sectors.

Medicines Australia says 'most' of its member companies support the adoption of the US system, where biologics are assigned a unique four-letter suffix, while the GBMA argues for maintenance of the current single naming system.

Yesterday was the first day on the job for new departmental secretaries, including Glenys Beauchamp PSM at Health and Dr Heather Smith PSM at Industry, Innovation and Science.

Health minister Greg Hunt has announced $20 million for a ground-breaking clinical trial targeting childhood cancers.

The proposal to fund access to MSD's Zostavax is actually wider than in Australia when you include the catch-up program.

The sector may or may not agree with Professor Wilson but, as one of the most influential people in the PBS and wider health policy in Australia, you have to assume the sector has made contact with the PBAC chair to, at the very least, better understand his perspective.

National are sticking with current policy while the Labour Party is proposing a significant additional investment in health and the creation of an 'early access to medicines scheme' 

Speculation health minister Greg Hunt is close to announcing major reforms to private health insurance and the pricing of prostheses highlights the challenge ahead for the pharmaceutical sector.

Some significant decisions on the scheduling of medicines with regulators maintaining erectile dysfunction medicines as prescription only while widening the availability of a popular reflux treatment. 

Ipsen's Peter Koetsier says Medicines Australia must take up the invitation of PBAC chair Professor Andrew Wilson to engage in a review and potential changes to National Medicines Policy.